Esomeprazole and Clopidogrel: Interaction Details
- Clopidogrel
- Plavix
- Esomeprazole
- NexiumNexium 24HREsomeprazole Strontium +6 more
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS
Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
- Dr. Brian Staiger, PharmD, BCPS, is a clinical pharmacist and pharmacotherapy specialist.
- AI-assisted, written
- AI is used only to summarize verified clinical information, never the open internet.
- Editorial policy
- How we build our interaction pages →
- Our AI policy →
A close look at the Esomeprazole and Clopidogrel interaction:
Esomeprazole
- Nexium
- Nexium 24HR
- Esomeprazole Strontium
- Riopan
- Nexium 24HR ClearMinis
- berkley and jensen heartburn treatment
- Esomeprazole Magnesium Delayed-Release 20 mg mini
- Esomeprazole Magnesium Delayed Release 20 mg mini
- Esomeprazole Magnesium Minis
What Happens When You Take Esomeprazole With Clopidogrel
What can happen when they are taken together (rated Major)
Reduced clopidogrel active exposure and reduced activity
Interaction Deep Dive
A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →
Esomeprazole should not be given together with clopidogrel, because it lowers concentrations of the active metabolite of clopidogrel and diminishes its antiplatelet effect whether the two drugs are taken at the same time or separated by 12 hours.2 Pantoprazole, lansoprazole, and dexlansoprazole have a smaller impact on clopidogrel's antiplatelet activity,2 as does RABEprazole when administered 4 hours after clopidogrel.3
For patients who need esomeprazole, an alternative antiplatelet agent may be considered.1 When the histamine-2 receptor raNITIdine was given with clopidogrel, it produced no significant change in clopidogrel's of aggregation.13
The Esomeprazole and Clopidogrel Interaction, Explained
Clopidogrel (Plavix) helps keep your blood from sticking together, which lowers the chance of a heart attack, stroke, or a clot in a stent. Here is the catch: Plavix has to be switched on by your liver before it works. Esomeprazole (Nexium) slows down the liver enzyme that does this switching. So when the two are taken together, Plavix can work less well, even if you take them hours apart.
Please keep taking both as prescribed for now. Talk with your pharmacist or doctor. Your care team has good options, such as a different heartburn medicine or a different , to keep you protected.
Mechanism: Clopidogrel is a requiring bioactivation. Esomeprazole inhibits CYP2C19, reducing active exposure () and of aggregation. The effect persists whether dosed concomitantly or 12 hours apart.
- Severity: Major. Onset: rapid. Evidence: established.
- Risk: diminished effect and potential for thrombotic events (e.g., stent thrombosis, MI, stroke).
- Management: avoid . If acid suppression is needed, pantoprazole, lansoprazole, dexlansoprazole, or rabeprazole (given 4 hours after clopidogrel) have less effect; ranitidine did not significantly alter platelet aggregation. If esomeprazole is required, consider alternative antiplatelet therapy.
See the 14 references behind this explanation ↓
From the HelloPharmacist Pharmacy Team
AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .
How we build these pages · How we use AI · Our editorial policy
Why Esomeprazole and Clopidogrel Interact
The likely mechanism
of -mediated of clopidogrel
How to Manage the Esomeprazole and Clopidogrel Interaction
This combination is usually avoided, and your care team has clear ways to handle it:
- Switching the stomach medicine to one with less effect on Plavix, such as pantoprazole, lansoprazole, dexlansoprazole, or rabeprazole (taken 4 hours after Plavix), or an H2 blocker.
- If you truly need Nexium, choosing a different medicine instead of Plavix.
What you can do: Keep taking both as prescribed until you speak with your pharmacist or prescriber. Spacing the doses apart does not fix this, so ask about switching. Mention any over-the-counter Nexium 24HR you use.
Management is individual — confirm any change with your pharmacist or prescriber.
Questions for Your Pharmacist
- Does my dose of Esomeprazole or Clopidogrel need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there another option that avoids this interaction?
Literature Reports
14 reports from the published literature. Each one is headed by the title of the published study it comes from.
What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.
-
Report 1 · Study title
Cerebrovascular outcomes with proton pump inhibitors and thienopyridines: a systematic review and meta-analysis
Treatment with a proton pump and thienopyridine (clopidogrel or prasugrel) compared with a thienopyridine alone significantly increased risk of stroke (adjusted hazard ratio (HR), 1.3; 95% CI, 1.04 to 1.61; 4 studies) and composite stroke/MI/cardiovascular death (adjusted HR, 1.23; 95% CI, 1.03 to 1.47; 8 studies) in a systematic review and metaanalysis of 22 studies (N=131,714). There was no significant difference in myocardial infarction (7 studies), cardiovascular death (6 studies) or all-cause mortality (8 studies). Patient followup occurred for 6 to 30 months (median, 12 months) within the studies.5
-
Report 2 · Study title
Prescribing information: PLAVIX oral tablets, clopidogrel bisulfate oral tablets
In dedicated drug-drug interaction studies, proton pump (dexlansoprazole, lansoprazole, pantoprazole, and omeprazole) use significantly reduced the of the clopidogrel active versus clopidogrel alone. Omeprazole use resulted in the greatest reduction in clopidogrel metabolite AUC, dexlansoprazole was associated with the least reduction.2
-
Report 3 · Study title
Influence of low-dose proton pump inhibitors administered concomitantly or separately on the anti-platelet function of clopidogrel
of clopidogrel 75 mg and esomeprazole 10 mg (administered together in the morning or 12 hours apart in the evening) resulted in a significant reduction in mean of aggregation compared with clopidogrel alone (43.2% vs 56%) measured 4 hours after the last clopidogrel dose on day 7, in a study of healthy Japanese subjects with different genotypes (N=41). A similar significant reduction was seen with omeprazole, lansoprazole, and RABEprazole when given together in the morning or separately in the evening. However, the reduction in inhibition of platelet aggregation was not significant with clopidogrel given after breakfast and RABEprazole administered after lunch (4 hours after or 20 hours prior to clopidogrel).3
-
Report 4 · Study title
Drug interaction between clopidogrel and ranitidine or omeprazole in stable coronary artery disease: a double-blind, double dummy, randomized study
In a study of patients with coronary artery disease, the of aggregation (IPA) of clopidogrel was significantly reduced with the addition of omeprazole (n=41; clopidogrel, 26.3%; combination therapy, 17.4%), but was not significantly changed with the addition of raNITIdine therapy (n=44; 32.6%; combination therapy, 30.1%). All patients received aspirin 100 mg daily prior to and during the study and had a baseline IPA measurement (0% for each group).
Patients then received clopidogrel 75 mg daily for one week prior to the second IPA measurement (time 1), then were randomized to receive combination therapy with clopidogrel and either omeprazole 20 mg twice daily or raNITIdine 150 mg twice daily for one week before the next IPA measurement (time 2). There was not a significant difference between groups for either time 1 or time 2. After excluding patients who were homozygous for 2C19*2 (loss-of-function) genotype, there was a significant difference between groups at time 2.4
-
Report 5 · Study title
Prescribing information: ESOMEPRAZOLE STRONTIUM oral delayed-release capsules, esomeprazole strontium oral delayed-release capsules
of esomeprazole magnesium 44.6 mg orally once daily with clopidogrel 75 mg orally daily (following a clopidogrel 300 mg loading dose) for 30 days in healthy subjects resulted in a 35% to 40% reduction in exposure to the active of clopidogrel. A corresponding change in of aggregation was observed.1
-
Report 6 · Study title
Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study
In a prospective study, significantly better response was observed with clopidogrel 150 mg concomitantly use with pantoprazole compared with omeprazole when platelet reactivity was assessed by the platelet reactivity index-vasoactive stimulated phosphoprotein (PRI-VASP), but not when assessed by adenosine diphosphate-induced aggregation (ADP-Ag), suggesting that the omeprazole-clopidogrel interaction may not be due to a proton-pump class effect. PRI-VASP precisely measures platelet activation/inactivation via phosphorylation of the P2Y12 receptor; whereas ADP-Ag is not specific solely to the P2Y12 receptor.
In this study, patients with successful stenting for non-ST segment acute coronary syndrome were discharged on aspirin 75 mg and clopidogrel 150 mg daily, then randomized (1:1) to either pantoprazole or omeprazole 20 mg/day. After 1 month, the pantoprazole arm had significantly better platelet response (less aggregation) to clopidogrel compared with the omeprazole arm as measured by PRI-VASP (36% +/- 20% vs 48% +/- 17%).
However, platelet response was not significantly different when measured by ADP-Ag (50 +/- 18% vs 52 +/- 15%) in the pantoprazole and omeprazole groups, respectively. Nonresponders to clopidogrel was significantly less with pantoprazole compared with omeprazole therapy (23% vs 44%; OR, 2.6; 95% CI, 1.2 to 6.2) emphasizing preferential choice of pantoprazole over omeprazole for clopidogrel-treated patients.6
-
Report 7
administration of clopidogrel with a proton pump (PPI) was associated with a significantly increased incidence and risk of major adverse cardiovascular events (MACE; a composite of myocardial infarction, unstable angina, transient ischemic attack/stroke, coronary revascularization, or cardiovascular death) compared with no concomitant PPI therapy, according to the Clopidogrel Medco Outcomes Study of 16,690 coronary-stent patients adherent to clopidogrel. Overall, patients on any PPI had a significantly higher risk of MACE (n=6828; 25.1%) compared with those receiving no PPI therapy (n=9862; 17.9%) with an adjusted hazard ratio (HR) of 1.51 (95% CI, 1.39 to 1.64).
After a 1-year follow-up, all PPIs were associated with a significant increase in MACE compared with no PPI therapy: pantoprazole (n=1653; 29.2% vs 17.9%; HR, 1.61; 95% CI, 1.41 to 1.88); esomeprazole (n=3257; 24.9% vs 17.9%; HR 1.57; 95% CI, 1.4 to 1.76); omeprazole (n=2307; 25.1% vs 17.9%; HR, 1.39; 95% CI, 1.22 to 1.57); and lansoprazole (n=785; 24.3% vs 17.9%; HR, 1.39; 95% CI, 1.16 to 1.67). Data on RABEprazole (n=298) were inconclusive due to limited power and sample size.7
-
Report 8 · Study title
Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome
The administration of clopidogrel and proton pump (PPI) was associated with an increased risk of death or rehospitalization for acute coronary syndrome (ACS) in a retrospective cohort study of Veterans Health Administration patients with acute myocardial infarction or unstable angina (n=8205). Patients discharged between October 1, 2003 and January 31, 2006 with clopidogrel prescriptions, based on pharmacy refill data, were reviewed.
Death and rehospitalization for ACS (primary endpoint) occurred in 29.8% of patients taking both clopidogrel and PPI at any point during the follow-up period (n=5244) versus 20.8% of patients taking clopidogrel without PPI (n=2961) (adjusted odds ratio (OR), 1.25; 95% confidence interval (CI), 1.11 to 1.41), rehospitalization for ACS occurred in 14.6% vs 6.9% (OR, 1.86; 95% CI, 1.57 to 2.20), revascularization procedures occurred in 15.5% vs 11.9% (OR, 1.49; 95% CI, 1.30 to 1.71), and death of all causes occurred in 19.9% vs 16.6% (OR, 0.91; 95% CI, 0.80 to 1.05) of patients, respectively. Of the PPI prescribed at discharge, 59.7% were for omeprazole, 2.9% for RABEprazole, 0.4% for lansoprazole, 0.2% for pantoprazole, and 36.7% for more than one type of PPI. Use of PPI without clopidogrel was not associated with death or rehospitalization for ACS (OR, 0.98; 95% CI, 0.85 to 1.13).8
-
Report 9 · Study title
A population-based study of the drug interaction between proton pump inhibitors and clopidogrel
In a population-based nested case-control study (n=2791) in Canada, treatment of clopidogrel and proton pump (PPI), other than pantoprazole, was associated with an increased risk of recurrent myocardial infarction (MI) in elderly patients who were treated for acute MI. Over a 69-month study period, patients who died or had recurrent MI within 90 days after discharged from the hospital (n=734) were matched with controls (n=2057) within a cohort of elderly patients (median age 76 years) who were discharged with clopidogrel after being treated for acute MI.
Compared with non-PPI users, the increased incidence of recurrent MI within 90 days was associated the concurrent therapy of clopidogrel with current use (within 30 days of the discharged date (index date)) of PPI (odds ratio (OR), 1.27; 95% CI 1.03 to 1.57), but not with earlier use (31 to 90 days before the index date) or remote use (91 to 180 days before the index date) of PPI. There were no association between recurrent MI and use of histamine-2 receptor , use of pantoprazole, and patients not treated with clopidogrel. Whereas use of PPI (other than pantoprazole) was associated with significant increased risk of recurrent MI (OR, 1.4; 95% CI, 1.10 to 1.77).9
-
Report 10 · Study title
Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study
In a double-blind, placebo-controlled trial of 140 patients undergoing coronary artery stent implantation, omeprazole 20 mg/day significantly decreased clopidogrel inhibitory effect on P2Y12 as assessed by vasodilator-stimulated phosphoprotein (VASP) phosphorylation assay. Clopidogrel exerts its effect by forming an inactivating disulfide bond with the platelet P2Y12 ADP receptor, which is then associated with dephosphorylation of VASP.
This dephosphorylation provides an index of platelet reactivity to clopidogrel in which the higher the platelet reactivity index (PRI), the more frequently thrombosis occurs (clopidogrel resistance). Consecutive patients received aspirin 75 mg/day and a loading dose (300 mg) of clopidogrel (followed by 75 mg/day), followed by randomization to either omeprazole or placebo for 7 days.
PRI was measured days 1 and 7, and data analyzed for 124 patients. The mean PRI was similar in both groups on day 1, 83.2%) for the placebo group compared with 83.9% for the omeprazole group.
On day 7, mean PRI was 39.8%) and 51.4%, respectively. Mean PRI variation in the placebo group was -43.3% and -32.6% in the omeprazole group. Sixteen patients (26.7%) in the placebo group were determined to be poor responders to clopidogrel compared with 39 (60.9%) in the omeprazole group (odds ratio 4.31; 95% confidence interval 2 to 9.2).10
-
Report 11 · Study title
Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel
A cross-sectional, observational study of 1000 patients receiving clopidogrel plus aspirin with or without proton pump (PPI) therapy (esomeprazole, omeprazole, or pantoprazole) revealed a significantly higher adenosine diphosphate (ADP)-induced aggregation with omeprazole, but not with esomeprazole or pantoprazole. Patients with coronary artery disease who were already receiving clopidogrel 75 mg/day plus aspirin and had undergone percutaneous coronary intervention at a median of 7 months before study inclusion were analyzed.
Among the 1000 patients, 268 were being treated with either esomeprazole (n=42), omeprazole (n=64), or pantoprazole (n=162) at the time of platelet function testing. Platelet aggregation was 295.5 AU*min for the omeprazole group compared with 220 AU*min for without-PPI group (p=0.001). Compared with no concomitant PPI treatment, platelet aggregation was not significantly different with esomeprazole (209 AU*min) or with pantoprazole (226 AU*min).11
-
Report 12 · Study title
Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel
An observational study of 300 patients receiving clopidogrel plus aspirin with or without proton pump (PPI) therapy, including esomeprazole (n=74) or pantoprazole (n=152), showed similar results for mean reactivity index (PRI) and adenosine diphosphate (ADP)-induced platelet aggregation. Patients with coronary artery disease who were already receiving clopidogrel 75 mg/day plus aspirin 100 mg/day and undergoing percutaneous coronary intervention were reviewed.
The mean PRI was 51% in patients receiving a PPI (n=226) compared with 49% in those not receiving a PPI (n=74). There was no significant difference in platelet aggregation in the PPI group compared with the no PPI group (45 units vs 41 units). Mean PRI and platelet aggregation were also not significantly different between patients treated with esomeprazole (54% and 41 units, respectively), with pantoprazole (50% and 47 units), and without a PPI (49% and 41 units).12
-
Report 13 · Study title
Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel
In a study of healthy men, treatment with raNITIdine did not significantly effect the , , or Tmax of clopidogrel or prasugrel when used in combination. Patients were randomized to receive either prasugrel (n=23; 60 mg oral loading dose then 10 mg orally daily for 7 days) or clopidogrel (n=24; 600 mg oral loading dose then 75 mg orally daily for 7 days) for two 9-day treatment periods separated by a 14-day washout period.
One period included treatment with only prasugrel or clopidogrel and the other treatment period included treatment with the same drug plus raNITIdine 150 mg orally twice daily started one day before the loading dose. of aggregation (IPA) of clopidogrel was not significantly effected by of raNITIdine. No clinically significant adverse effects occurred during the study.13
-
Report 14 · Study title
Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors
A retrospective, claims-based analysis of medical and pharmacy databases for acute myocardial infarction (MI) rates in members receiving clopidogrel with or without concurrent proton pump (PPI) therapy revealed a 1-year acute MI rate of 1.38% in the control group (no PPI exposure), 3.08% (low PPI exposure based on adherence rate), and 5.03% (high PPI exposure). When the control group MI incidence was used as the expected MI rate, the difference in MI rates between control and high exposure groups was significant (p less than 0.05).
Analysis also indicated small but significant comorbidity differences between the groups, including more patients with preexisting hypertension, diabetes, and overall severity of illness at initiation of clopidogrel in the high exposure group. When comorbidity differences were adjusted out of analysis, the differences in acute MI rates remained significant; 2.6% (95% confidence interval (CI), 1.01 to 4.19) of those in the control group experienced MI events compared with 11.38% (95% CI, 8.69 to 14.07) in the high PPI exposure group.14
Esomeprazole and Clopidogrel: Common Questions
How serious is the Esomeprazole and Clopidogrel interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How is the Esomeprazole and Clopidogrel interaction managed?
This combination is usually avoided, and your care team has clear ways to handle it: Switching the stomach medicine to one with less effect on Plavix, such as pantoprazole, lansoprazole, dexlansoprazole, or rabeprazole (taken 4 hours after Plavix), or an H2 blocker. If you truly need Nexium, choosing a different medicine instead of Plavix. What you can do: Keep taking both as prescrib… Management is individual — always follow your own care team's guidance.
How far apart should I take Esomeprazole and Clopidogrel?
The interaction record says to take esomeprazole and clopidogrel 12 hours apart.
Your pharmacist can help you fit this into the times you take your other medicines.
Is there an alternative to taking Esomeprazole with Clopidogrel?
This combination is usually avoided, and your care team has clear ways to handle it: Switching the stomach medicine to one with less effect on Plavix, such as pantoprazole, lansoprazole, dexlansoprazole, or rabeprazole (taken 4 hours after Plavix), or an H2 blocker.
Only your prescriber can decide whether a change fits you, so talk with them before changing either medicine.
How quickly could this interaction happen?
The documented onset is "rapid". Effects can appear quickly, often within about 24 hours of combining the drugs.
How strong is the evidence for this interaction?
The evidence is graded "established". Well documented — supported by controlled studies or strong clinical data.
Ask About the Esomeprazole and Clopidogrel Interaction
Ask in your own words about taking Esomeprazole and Clopidogrel together. The answer comes from this page’s interaction record and both drugs’ own information.
This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.
AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.
References (14)
- Product Information: ESOMEPRAZOLE STRONTIUM oral delayed-release capsules, esomeprazole strontium oral delayed-release capsules. Amneal Pharmaceuticals (per FDA), Glasgow, KY, 2013. DailyMed
- Product Information: PLAVIX(R) oral tablets, clopidogrel bisulfate oral tablets. sanofi-aventis US LLC (per FDA), Bridgewater, NJ, 2022. DailyMed
- Furuta T, Sugimoto M, Kodaira C, et al: Influence of low-dose proton pump inhibitors administered concomitantly or separately on the anti-platelet function of clopidogrel. J Thromb Thrombolysis 2017; 43(3):333-342. PubMed
- Furtado RH, Giugliano RP, Strunz CM, et al: Drug interaction between clopidogrel and ranitidine or omeprazole in stable coronary artery disease: a double-blind, double dummy, randomized study. Am J Cardiovasc Drugs 2016; 16(4):275-284. DOI
- Malhotra K, Katsanos AH, Bilal M, et al: Cerebrovascular outcomes with proton pump inhibitors and thienopyridines: a systematic review and meta-analysis. Stroke 2018; 49(2):312-318. PubMed
- Cuisset T, Frere C, Quilici J, et al: Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. J Am Coll Cardiol 2009; 54(13):1149-1153.
- The Society for Cardiovascular Angiography and Interventions: A National Study of the Effect of Individual Proton Pump Inhibitors on Cardiovascular Outcomes in Patients Treated with Clopidogrel Following Coronary Stenting: The Clopidogrel Medco Outcomes Study. The Society for Cardiovascular Angiography and Interventions. Washington, DC. 2009.
- Ho PM, Maddox TM, Wang L, et al: Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301(9):937-944. PubMed
- Juurlink DN, Gomes T, Ko DT, et al: A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009; E Pub:1-. DOI
- Gilard M, Arnaud B, Cornily JC, et al: Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008; 51(3):256-260.
- Sibbing D, Morath T, Stegherr J, et al: Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009; 101(4):714-719. DOI
- Siller-Matula JM, Spiel AO, Lang IM, et al: Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009; 157(1):148e1-148e5. PubMed
- Small DS, Farid NA, Li YG, et al: Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. Curr Med Res Opin 2008; 24(8):2251-2257. DOI
- Pezalla E, Day D, & Pulliadath I: Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. J Am Coll Cardiol 2008; 52(12):1038-1039. PubMed
Other Serious Interactions of Esomeprazole and Clopidogrel
Also serious with Clopidogrel
- AbrocitinibContraindicated
- Defibrotide InjectionContraindicated
- Acetaminophen and CodeineMajor
- OmeprazoleMajor
Also serious with Esomeprazole
These Medications Also Interact With Supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
With Clopidogrel
- GrapefruitMajor
- St. John's WortMajor
- Activated CharcoalMajor
- PiracetamMajor
- Vitamin EModerate
- SeleniumModerate
- GingerModerate
- TurmericModerate
- + 309 more
With Esomeprazole
- GrapefruitMajor
- St. John's WortMajor
- Activated CharcoalMajor
- Vitamin EModerate
- GingerModerate
- TurmericModerate
- Black PepperModerate
- GrapeModerate
- + 151 more
Check everything you take with our drug–supplement interaction checker.
Still Have Questions About This Combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
About This Library
Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →
What Each Rating Means
Severity Levels
- Contraindicated These should generally not be used together.
- Major Potentially serious — often needs a change or close monitoring. This interaction.
- Moderate Can be significant — usually manageable with monitoring.
- Minor Usually limited clinical impact.
Evidence Grades
- EstablishedWell documented — supported by controlled studies or strong clinical data. This interaction.
- ProbableGood supporting evidence, though not definitively proven.
- SuspectedSome evidence suggests this interaction, but it is not well established.
- PossibleLimited or conflicting evidence; the interaction may occur.
- TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.
How Soon It Shows
- RapidEffects can appear quickly, often within about 24 hours of combining the drugs. This interaction.
- DelayedEffects tend to build up gradually over days to weeks.
- UnspecifiedThe timing of this interaction is not well characterized.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.